The Egyptian Journal of Haematology

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 43  |  Issue : 1  |  Page : 10--18

Thrombin antithrombin complex assessment in patients with chronic hemolytic anemia as a marker for the activity of coagulation


Ibrahim Y Abdel-Messih1, Nevine G Andrawes2, Yasmin N El-Sakhawy1, Nesma A Safwat1, Yasmin H Ibrahim1 
1 Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2 Department of Pediatrics, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Yasmin N El-Sakhawy
Department of Clinical Pathology, Faculty of Medicine, Ain Shams University, Cairo
Egypt

Background Hypercoagulability in chronic hemolytic anemia, namely, β-thalassemia major (TM), β-thalassemia intermedia (TI), and sickle cell disease (SCD), is well recognized. Activation of coagulation results in thrombin formation which in turn is inactivated by complex formation with its major inhibitor thrombin antithrombin complex (TAT). As a result, TAT is considered a coagulation marker which confirms the hypercoagulability state. Aim The aim of this study was to measure TAT as a coagulation activation marker in patients with β-TM, β-TI, and SCD and to correlate TAT levels with their clinicolaboratory parameters. Patients and methods A total of 60 children and adolescents having β-thalassemia syndromes and SCD were recruited from pediatric hematology clinic, Ain Shams University. They underwent routine complete blood picture and hemolytic profile in addition to TAT. Results The TAT was significantly higher in all patients (164.13±42.47 µg/l) compared with controls (106.75±21. 35 μg/l). In the thalasssemia group, the TAT level was 156.45±42.71 µg/l, whereas in patients with SCD, it was 179.50±38.52 µg/l. On comparing patients with thalassemia and those with SCD, there was a significant difference (P<0.05). However, measured TAT levels in patients with TM versus those with TI were 151.11±26.07l versus 167.54±65.25 µg/l, respectively. Comparison of TAT level between patients with TM and TI revealed no statistically significant difference. TAT was significantly correlated with mean corpuscular volume, mean corpuscular hemoglobin, and total and indirect bilirubin levels in all patients. Conclusion β-Thalassemia syndromes and SCD are associated with increased coagulation activity, and this activity is correlated with the level of hemolysis.


How to cite this article:
Abdel-Messih IY, Andrawes NG, El-Sakhawy YN, Safwat NA, Ibrahim YH. Thrombin antithrombin complex assessment in patients with chronic hemolytic anemia as a marker for the activity of coagulation.Egypt J Haematol 2018;43:10-18


How to cite this URL:
Abdel-Messih IY, Andrawes NG, El-Sakhawy YN, Safwat NA, Ibrahim YH. Thrombin antithrombin complex assessment in patients with chronic hemolytic anemia as a marker for the activity of coagulation. Egypt J Haematol [serial online] 2018 [cited 2020 Jan 28 ];43:10-18
Available from: http://www.ehj.eg.net/article.asp?issn=1110-1067;year=2018;volume=43;issue=1;spage=10;epage=18;aulast=Abdel-Messih;type=0